시장보고서

상품코드

1790205

세포배양 보충제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Cell Culture Supplements Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세포배양 보충제 시장 개요

세포 배양 보충제 세계 시장 규모는 2024년 25억 3,000만 달러로 평가되었습니다. 2033년에는 71억 4,000만 달러에 달하고, 2025-2033년 12.74%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 성장의 원동력은 바이오의약품 수요 증가, 세포배양 기술의 발전, 맞춤형 의료와 재생치료에 대한 관심 증가에 기인합니다.

3D 세포배양과 오가노이드 모델의 발전

3D 세포배양 시스템과 오가노이드 기술의 채택 확대가 세계 세포배양 보충제 시장 수요를 크게 견인하고 있습니다. 기존 2D 배양과 달리 3D 모델은 생체 내 세포 환경을 정확하게 표현하기 때문에 연구자들은 조직 발달, 암 전이, 약물 반응과 같은 복잡한 생물학적 과정을 더 잘 연구할 수 있습니다. 특히 오가노이드는 실제 인체 장기의 구조와 기능을 재현하기 때문에 재생의료 및 질병 모델링에 있어 필수적인 도구가 되고 있습니다. 예를 들어, 2025년 7월 Scientific Reports에 발표된 연구는 감염성 질환 연구를 위한 유기체 기반 모델의 발전에 대해 자세히 설명합니다. 줄기세포에서 유래한 이 3차원 세포 배양 시스템은 기존 2차원 배양 시스템보다 생리학적으로 더 적합한 인간 장기 시뮬레이션을 기술하고 있습니다. 이 연구는 신약개발을 가속화하고 동물모델에 대한 의존도를 줄일 수 있는 오가노이드 기술의 잠재력을 강조하고 있습니다. 이러한 첨단 모델에서는 세포의 분화, 생존력, 기능을 지원하기 위해 성장인자, 세포외 기질 단백질, 정의된 배지 성분 등 매우 특수한 배양 조건과 특수한 보충제가 필요합니다.

제약회사, 생명공학 기업, 학술 기관은 신약 개발의 효율성을 높이고 동물 실험에 대한 의존도를 줄이기 위해 이러한 혁신적인 모델을 점점 더 많이 활용하고 있습니다. 그 결과, 3D 배양이나 오가노이드와 같은 복잡한 시스템에 맞춘 세포배양 보조제에 대한 수요가 크게 증가할 것으로 예상되며, 차세대 바이오 의료 연구 및 치료제 개발의 중요한 실현자로서 이 부문의 입지가 강화될 것으로 예측됩니다.

재생의료와 줄기세포 연구의 급성장

재생의료 및 줄기세포 연구 부문의 확대는 세계 세포배양 보충제 산업을 이끄는 주요 촉진제입니다. 재생의료는 신체의 치유 메커니즘을 이용하여 손상된 조직이나 장기를 복구하거나 대체하는 것에 초점을 맞추고 있으며, 대부분 줄기세포를 이용한 치료법이 사용되고 있습니다. 줄기세포는 자기복제와 여러 세포형으로 분화할 수 있는 독특한 능력을 가지고 있어 신경퇴행성 질환, 심혈관 질환, 부상 등 다양한 증상 치료에 유용하게 활용되고 있습니다. 예를 들어, 2025년 6월 '뉴잉글랜드 저널 오브 메디신(New England Journal of Medicine)'지에 보고된 임상시험에서 1형 당뇨병 치료에 큰 진전이 있었습니다고 발표되었습니다. 연구 결과, 실험실에서 배양한 췌도세포를 한 번만 주입하면 환자가 독립적으로 충분한 인슐린을 생산할 수 있다는 사실이 입증됐습니다. 1년 이내에 12명 중 10명이 인슐린 보충이 필요 없어져 당뇨병 관리의 패러다임 전환이 일어날 수 있음을 보여주었습니다. 이 섬세한 줄기세포를 배양하기 위해서는 다능성 또는 다능성을 유지하기 위한 고도의 특수한 보충제가 필요합니다. 이러한 보충제는 필수 영양소, 성장인자, 사이토카인, 신호전달 분자 등을 공급하여 세포의 증식, 생존, 분화 조절을 촉진합니다.

세계적으로 줄기세포 치료 임상시험이 급증하고, 규제 당국의 승인도 증가함에 따라 신뢰할 수 있고 확장성이 높은 세포 배양 시스템에 대한 수요가 가속화되고 있습니다. 조직공학과 맞춤형 의료의 접근법은 첨단 보충제를 통해 최적화된 세포 배양 조건에 크게 의존하고 있습니다. 보충제는 새로운 재생 치료 및 줄기세포 응용의 성공과 안전성을 보장하는 데 중요한 역할을 하기 때문에 이러한 추세는 시장의 강력한 성장을 유지할 것으로 예측됩니다.

지역별 시장 점유율 분석, 2023년과 2033년
지역별 시장 대시보드
시장 규모, 예측 동향 분석, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

기업/경쟁 분류
전략 매핑
기업 시장 현황 분석, 2024년
기업 개요/상장기업
- Merck KGaA
- Thermo Fisher Scientific Inc.
- HiMedia Laboratories
- Danaher
- Sartorius AG
- Corning Inc.
- R&D Systems(Bio-Techne)
- STEMCELL Technologies
- Repligen Corporation
- Proteintech Group, Inc

LSH 25.08.25

Cell Culture Supplements Market Summary

The global cell culture supplements market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 7.14 billion by 2033, growing at a CAGR of 12.74% from 2025 to 2033. This growth is driven by increasing demand for biopharmaceuticals, advancements in cell culture technology, and the rising focus on personalized medicine and regenerative therapies.

Advancements in 3D Cell Culture and Organoid Models

The growing adoption of 3D cell culture systems and organoid technologies significantly drives market demand for global cell culture supplements. Unlike conventional 2D cultures, 3D models accurately represent in vivo cellular environments, allowing researchers to study complex biological processes such as tissue development, cancer metastasis, and drug responses better. Organoids, in particular, have become vital tools in regenerative medicine and disease modeling, as they replicate the architecture and function of real human organs. For instance, a study published in Scientific Reports in July 2025 detailed the advancements in organoid-based models for infectious disease research. These 3D cell culture systems, derived from stem cells, offer more physiologically relevant human organ simulations than traditional 2D cultures. The study underscores the potential of organoid technology to accelerate drug discovery and reduce reliance on animal models. These advanced models require highly specific culture conditions and specialized supplements, including growth factors, extracellular matrix proteins, and defined media components to support cell differentiation, viability, and function.

Pharmaceutical companies, biotech firms, and academic institutions increasingly turn to these innovative models to improve drug discovery efficiency and reduce dependence on animal testing. As a result, the demand for cell culture supplements tailored to complex systems like 3D cultures and organoids is expected to grow significantly, reinforcing the segment's position as a critical enabler of next-generation biomedical research and therapeutic development.

Rapid Growth in Regenerative Medicine and Stem Cell Research

The expanding regenerative medicine and stem cell research field is a major driver boosting the global cell culture supplements industry. Regenerative medicine focuses on repairing or replacing damaged tissues and organs by harnessing the body's healing mechanisms, often through stem cell-based therapies. Stem cells possess the unique ability to self-renew and differentiate into multiple cell types, making them invaluable for treating various conditions, including neurodegenerative diseases, cardiovascular disorders, and injuries. For instance, a clinical trial reported in The New England Journal of Medicine in June 2025 announced a significant advancement in type 1 diabetes treatment. Their study demonstrated that a single infusion of lab-grown pancreatic islet cells enabled patients to produce sufficient insulin independently. Within a year, 10 out of 12 participants no longer required supplemental insulin, marking a potential paradigm shift in diabetes management. Culturing these delicate stem cells requires highly specialized supplements that maintain their pluripotency or multipotency. These supplements provide essential nutrients, growth factors, cytokines, and signaling molecules that promote cell proliferation, viability, and controlled differentiation.

The surge in clinical trials and increasing regulatory approvals of stem cell therapies worldwide are accelerating the demand for reliable and scalable cell culture systems. Tissue engineering and personalized medicine approaches rely heavily on optimized cell culture conditions supported by advanced supplements. This trend is expected to sustain strong growth in the market, as supplements play a crucial role in ensuring the success and safety of emerging regenerative treatments and stem cell applications.

Global Cell Culture Supplements Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global cell culture supplements market report on the basis of product, application, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Serum-based Supplements
Protein-based & Recombinant Supplements
Chemically Defined Supplements
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Biopharmaceutical Manufacturing
Cell & Gene Therapy
Drug Discovery
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Cell Culture Media Manufacturers
Pharmaceutical & Biotechnology Companies
CDMOs/ CMOs & CROs
Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Application Segment
- 1.2.3. End Use Segment
1.3. Information Analysis
- 1.3.1. Market formulation & data visualization
1.4. Data Validation & Publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape

Chapter 3. Cell Culture Supplements Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Advancements in 3D cell culture and organoid models
  - 3.2.1.2. Rapid growth in regenerative medicine and stem cell research
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High cost of GMP-grade and specialty supplements
  - 3.2.2.2. Regulatory and standardization challenges
3.3. Cell Culture Supplements Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Cell Culture Supplements Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Cell Culture Supplements Market Product Movement Analysis
4.3. Global Cell Culture Supplements Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Serum-Based Supplements
- 4.4.1. Serum-Based Supplements market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Protein-Based & Recombinant Supplements
- 4.5.1. Protein-Based & Recombinant Supplements market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Chemically Defined Supplements
- 4.6.1. Kits & reagents market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Others
- 4.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Cell Culture Supplements Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Cell Culture Supplements Market Application Movement Analysis
5.3. Global Cell Culture Supplements Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Biopharmaceutical Manufacturing
- 5.4.1. Biopharmaceuticals manufacturing market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Cell & Gene Therapy
- 5.5.1. Cell & gene therapy market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Drug Discovery
- 5.6.1. Drug discovery market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Others
- 5.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Cell Culture Supplements Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Cell Culture Supplements Market End Use Movement Analysis
6.3. Global Cell Culture Supplements Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Cell Culture Media Manufacturers
- 6.4.1. Cell culture media manufacturers companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Pharmaceutical & Biotechnology Companies
- 6.5.1. Pharmaceuticals & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
6.6. CDMOs/ CMOs & CROs
- 6.6.1. CDMOs/ CMOs & CROs market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Academic & Research Institutes
- 6.7.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Cell Culture Supplements Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2023 & 2033
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Competitive scenario
  - 7.4.1.3. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Competitive scenario
  - 7.4.2.3. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Competitive scenario
  - 7.4.3.3. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
- 7.5.1. UK
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Competitive scenario
  - 7.5.1.3. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Competitive scenario
  - 7.5.4.3. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Competitive scenario
  - 7.5.5.3. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Norway
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Competitive scenario
  - 7.5.6.3. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Competitive scenario
  - 7.5.7.3. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Denmark
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Competitive scenario
  - 7.5.8.3. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Competitive scenario
  - 7.6.1.3. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Competitive scenario
  - 7.6.4.3. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Competitive scenario
  - 7.6.5.3. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. Thailand
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Competitive scenario
  - 7.6.6.3. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Competitive scenario
  - 7.7.1.3. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. MEA
- 7.8.1. South Africa
  - 7.8.1.1. Key country dynamics
  - 7.8.1.2. Competitive scenario
  - 7.8.1.3. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Competitive scenario
  - 7.8.2.3. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Competitive scenario
  - 7.8.3.3. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Competitive scenario
  - 7.8.4.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
- 8.4.1. Merck KGaA
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product/Service benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Thermo Fisher Scientific Inc.
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product/Service benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. HiMedia Laboratories
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product/Service benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. Danaher
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product/Service benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. Sartorius AG
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product/Service benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. Corning Inc.
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product/Service benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. R&D Systems (Bio-Techne)
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product/Service benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. STEMCELL Technologies
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product/Service benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Repligen Corporation
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product/Service benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. Proteintech Group, Inc
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Product/Service benchmarking
  - 8.4.10.4. Strategic initiatives

세포배양 보충제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Cell Culture Supplements Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세포배양 보충제 시장 변수, 동향, 범위

제4장 세포배양 보충제 시장 : 제품별, 추정·동향 분석

제5장 세포배양 보충제 시장 : 용도별, 추정·동향 분석

제6장 세포배양 보충제 시장 : 최종 용도별, 추정·동향 분석

제7장 세포배양 보충제 시장 : 지역별, 추정·동향 분석